protein
| importin-alpha subunit of the nuclear transport signal receptor ![](pubmed.jpg) |
|
Rad51 ![](pubmed.jpg) |
|
p32 and p65 BRCA1 interacting proteins, cyclin A, cyclin B1, cyclin D1, cdc2, cdk2 and E2F ![](pubmed.jpg) |
|
BRAP2 ![](pubmed.jpg) |
|
BAP1 ![](pubmed.jpg) |
|
p53 ![](pubmed.jpg) ![](pubmed.jpg) |
|
a component of the RNA polymerase II (Pol II) holoenzyme ![](pubmed.jpg) |
|
BRCA2 ![](pubmed.jpg) |
|
c-Myc ![](pubmed.jpg) |
|
CtIP ![](pubmed.jpg) ![](pubmed.jpg) |
|
gamma-tubulin ![](pubmed.jpg) |
|
CtBP ![](pubmed.jpg) |
|
RbAp46 and RbAp48, HDAC1 and HDAC2 ![](pubmed.jpg) |
|
hRad50-hMre11-p95 complex ![](pubmed.jpg) |
|
hypophosphorylated form of pRb ![](pubmed.jpg) |
|
CBP/p300 ![](pubmed.jpg) |
|
BRCA1-associated genome surveillance complex: MSH2, MSH6, MLH1, ATM, BLM, and the RAD50-MRE11-NBS1 protein complex, and DNA replication factor C, RFC ![](pubmed.jpg) |
|
RNA polymerase II ![](pubmed.jpg) |
|
STAT1 ![](pubmed.jpg) |
|
valosin-containing protein, VCP ![](pubmed.jpg) |
|
ZBRK1 ![](pubmed.jpg) |
|
ATF1 ![](pubmed.jpg) |
|
androgen receptor, AR and p160 ![](pubmed.jpg) |
|
checkpoint kinase ATR ![](pubmed.jpg) |
|
JAK1 and JAK2 ![](pubmed.jpg) |
|
FANCD2 ![](pubmed.jpg) |
|
BACH1 ![](pubmed.jpg) |
|
retinoblastoma suppressor (Rb)-associated protein 46, RbAp46 ![](pubmed.jpg) |
|
c-Fos oncogene regulator Elk-1 ![](pubmed.jpg) |
|
LMO4 ![](pubmed.jpg) |
|
GADD45 ![](pubmed.jpg) |
|
N-Myc-interacting protein, Nmi ![](pubmed.jpg) |
|
c-Abl ![](pubmed.jpg) |
|
JUNB and JUND ![](pubmed.jpg) |
|
alpha- and beta-tubulin ![](pubmed.jpg) |
|
Fanconi anemia protein, FANCA ![](pubmed.jpg) |
|
Acetyl Coenzyme A (CoA) Carboxylase alpha, ACCA ![](pubmed.jpg) |
|
ER-alpha ![](pubmed.jpg) |
|
Stat5a ![](pubmed.jpg) |
|
phosphatase 1alpha, PP1alpha ![](pubmed.jpg) |
|
Sp1 ![](pubmed.jpg) |
|
p65/RelA ![](pubmed.jpg) |
|
four and a half LIM-only protein 2, FHL2 ![](pubmed.jpg) |
|
BARD1/BRCC45/BRCC36 ![](pubmed.jpg) |
|
IFI16 ![](pubmed.jpg) |
|
p53 ![](pubmed.jpg) |
|
Aurora-A ![](pubmed.jpg) |
|
FHL2 ![](pubmed.jpg) |
|
zinc-finger-containing protein NUFIP ![](pubmed.jpg) |
|
nucleolar phosphoprotein nucleophosmin/B23, NPM ![](pubmed.jpg) |
|
SWI/SNF enzymes ![](pubmed.jpg) |
|
mitogen-activated protein kinase (MAPK) kinase kinase 3, MEKK3 ![](pubmed.jpg) |
|
TRAP220 ![](pubmed.jpg) |
|
Cdk-activating kinase, CAK ![](pubmed.jpg) |
|
Smad3 |
|
hGCN5, TRRAP, and hMSH2/6 ![](pubmed.jpg) |
|
poly(A)-binding protein 1, PABP ![](pubmed.jpg) |
|
cyclin D1 ![](pubmed.jpg) |
|
Abraxas and RAP80 ![](pubmed.jpg) |
|
TR-interacting protein, ATRIP ![](pubmed.jpg) |
|
CCDC98 ![](pubmed.jpg) |
|
aryl hydrocarbon receptor, AhR ![](pubmed.jpg) |
|
ERK1/2 ![](pubmed.jpg) |
|
p14ARF ![](pubmed.jpg) |
|
Ku80 ![](pubmed.jpg) |
|
vitamin D receptor, VDR ![](pubmed.jpg) |
|
Rap80 ![](pubmed.jpg) |
|
NBA1 ![](pubmed.jpg) |
|
Mediator of Rap80 Interactions and Targeting 40 kd, MERIT40 ![](pubmed.jpg) |
|
PALB2 ![](pubmed.jpg) |
|
NINL (![](pubmed.jpg) |
|
centrosomal protein Nlp ![](pubmed.jpg) |
|
E2s ![](pubmed.jpg) |
|
deleted in breast cancer 1, DBC1/KIAA1967 ![](pubmed.jpg) |
|
FANCJ ![](pubmed.jpg) |
|
BRD7 ![](pubmed.jpg) |
|
MRG15 ![](pubmed.jpg) |
|
UBXN1 ![](pubmed.jpg) |
|
HERC2 ![](pubmed.jpg) |
|
UE2I ![](pubmed.jpg) |
|
TFII-I ![](pubmed.jpg) |
|
BCL2 ![](pubmed.jpg) |
|
KIAA0101 ![](pubmed.jpg) |
|
YY1 binds to the promoter of BRCA1, and its overexpression resulted in increased expression of BRCA1 and a number of BRCA1 downstream genes ![](pubmed.jpg) |
|
Cockayne syndrome B, CSB ![](pubmed.jpg) |
|
BARD1 ![](pubmed.jpg) ![](pubmed.jpg) |
|
AP2-alpha, PAX2 and ZF5 ![](pubmed.jpg) |
|
CDK1 ![](pubmed.jpg) |
|
interaction between the breast/ovarian tumor suppressor gene BRCA1 and the transcription factor GATA3, an interaction, which is important for normal breast differentiation ![](pubmed.jpg) |
|
gamma tubulin, CRM1, and Aurora A ![](pubmed.jpg) |
|
BRCA1 antagonises TP53BP1-dependent DNA repair in S phase by inhibiting its interaction with chromatin proximal to damage sites ![](pubmed.jpg) |
|
claspin (![](pubmed.jpg) |
|
loss of HSP90AA1 function abolishes BRCA1-dependent DSB repair ![](pubmed.jpg) |
|
SKP1 regulates BRCA1 protein stability ![](pubmed.jpg) |
|
FBXO44 is an important protein that influences BRCA1 protein level ![](pubmed.jpg) |
|
BRCA1 heterodimerizes with its partner protein, BARD1, via the RING domain present in both proteins ![](pubmed.jpg) |
|
BRCA1-dependent degradation of cyclin B and CDC25C is reversed by proteasome inhibitors and is enhanced following DNA damage, which may represent a possible mechanism to prevent cyclin B and CDC25C accumulation, a requirement for mitotic entry ![](pubmed.jpg) |
|
RBBP8 interacts with NBN and BRCA1, and connects CDK and ATM to regulate homologous recombination (HR)-mediated double-strand break repair ![](pubmed.jpg) |
|
ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor ![](pubmed.jpg) |
|
DCLRE1B is a nuclease required for efficient localization of the DNA repair proteins, FANCD2 and BRCA1 ![](pubmed.jpg) |
|
BRCA1 downregulates the kinase activity of PLK1 by modulating the dynamic interactions of AURKA, BORA, and PLK1 ![](pubmed.jpg) |
|
TP53BP1 recruitment requires the direct recognition of a DSB-specific histone code and its influence on pathway choice is mediated by mutual antagonism with BRCA1 ![](pubmed.jpg) |
|
KDM5B is required for efficient DSB repair and for the recruitment of XRCC6 and BRCA1, the essential component of nonhomologous end-joining and homologous recombination, respectively ![](pubmed.jpg) |
|
FAM175A is a BRCA1 BRCT domain-interacting protein, playing a role in tumor suppression ![](pubmed.jpg) |
|
BRCA1 and BLM interact with RAD50 predominantly in S- and G2-phases, respectively ![](pubmed.jpg) |
|
functions as a bona fide tumor suppressor by regulating the protein stability and function of BRCA1 in breast cancer ![](pubmed.jpg) |
|
BRCA1 and BRIP1 cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of PLK1 ![](pubmed.jpg) |
|
gain of function mutant TP53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression ![](pubmed.jpg) |
|
CEP72 is a novel BRCA1-interacting protein ![](pubmed.jpg) |
|
high levels of CEP72 counteract CHEK2 as a positive regulator of BRCA1 to ensure proper mitotic microtubule assembly ![](pubmed.jpg) |
|
BABAM1 is an essential component of the RAP80 ubiquitin recognition complex that targets BRCA1 to DNA damage sites ![](pubmed.jpg) |
|
mitotic function of BRCA1 depends on its phosphorylation by the tumor-suppressor kinase CHEK2 and this regulation is required to ensure normal microtubule plus end assembly rates within mitotic spindles ![](pubmed.jpg) |
|
dual molecular mechanism by which the CHEK2-BRCA1 axis restrains oncogenic AURKA activity during mitosis and BRCA1 itself is a target for AURKA relevant for chromosomal instability (CIN)![](pubmed.jpg) |
|
ERCC5 is a partner of BRCA1 and BRCA2 in maintaining genomic stability through homologous recombination (HRR) ![](pubmed.jpg) |
|
BRCA1 (FANCS), MDC1, and RNF8 are required for BRCA2 (FANCD1) and SLX4 (FANCP) accumulation on the sex chromosomes during meiosis ![](pubmed.jpg) |
|
ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair ![](pubmed.jpg) |
|
ACLY phosphorylation and nuclear localization are necessary for its role in promoting BRCA1 recruitment ![](pubmed.jpg) |
|
both BRCA1 and BARD1 bind DNA and interact with RAD51, and BRCA1-BARD1 enhances the recombinase activity of RAD51 ![](pubmed.jpg) |
|
BRCA1 promotes oxidative metabolism by degrading POU2F1, a transcription factor with proglycolytic and tumorigenic effects ![](pubmed.jpg) |
|
regulation of BRCA1-BARD1 heterodimerization through SIRT2 deacetylation, elucidating a critical upstream signaling event directing BRCA1-BARD1 heterodimerization, which facilitates HR and tumor suppression ![](pubmed.jpg) |
|
novel function of the BRCA1-BARD1 complex in the regulation of TOP2B and Pol II-mediated gene expression ![](pubmed.jpg) |